polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: The intervention group will receive DASH food pattern, and at the same time, dietary recommendations for receiving foods with low glycemic index, including the sele
The consumption of foods from the dairy group that are combined with sugars will be limited
and also from the grain group, foods with high glycemic index will be limited, and it will be recommended to choose and consume foods with a lower glycemic index in this group. Intervention 2: Control
Sponsors
Oroumia University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: patients with polycystic ovary syndrome Age range (18-45 years)
Exclusion criteria
Exclusion criteria: Pregnant Patients or Patients who intend to become pregnant during the study Patients with pituitary dysfunction, adrenal hyperplasia, androgen-secreting tumors Patients with diabetes Patients with thyroid dysfunction Patients taking therapeutic hormones or drugs affecting weight Patients with malignant tumors and HIV infection Patients with a history of kidney stones Patients with liver diseases Patients with gout Patients with kidney diseases Patients undergoing hemodialysis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| LH hormone. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;FSH hormone. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Testosterone hormone. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Hs-CRP. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Fasting blood glucose. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Insulin. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Triglycerides. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;HDL-cholesterol. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;LDL-cholesterol. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Total cholesterol. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: Enzymatic method.;Weight. Timepoint: The beginning of the study (before the start of the intervention) and 12 weeks after the start of the intervention. Method of measurement: scales. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMajid Manafi
Oroumia University of Medical Sciences
Outcome results
None listed